Jagsi R, et al. - Given that locoregional control for inflammatory breast cancers and chest wall recurrences is suboptimal and preclinical studies have suggested a favorable therapeutic index when poly (ADP-ribose) polymerase inhibitors are used as radiosensitizers, researchers herein focused on establishing appropriate dosing and confirming safety of this treatment strategy. Patients who had undergone complete surgical resection for inflammatory or locally recurrent breast cancer, were given treatment including veliparib and concurrent radiotherapy (RT) to the chest wall and regional lymph nodes. Even at the highest tested dose, severe acute toxicity did not exceed 30% but grade 3 adverse events were reported at 3 years in nearly half of surviving patients, a finding that highlights the importance of long-term monitoring of toxicity in trials of radiosensitizing agents.